Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015

Description: Prostate cancer has emerged as a disease with one of the highest incidences and mortality rates in males across the world. This situation has created a large unmet medical demand for better therapeutics by patients suffering from prostate cancer due to modest response generated by presently available therapeutics. Hormone based therapeutics and chemotherapeutics helped in improving the patient's condition but they have side effects and modest pharmacological benefits reflecting necessity for better product. Pharmaceutical companies focused their efforts to resolve this problem by increasing research and development activities by diverging more funds in this segment. As a result, prophylactic prostate cancer vaccine was developed and introduced in market which is going to witness competition from innovative products in next few years.

Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical treatment. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long-term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years.

Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients.

Prostate cancer vaccines are prophylactic in nature due to which they can prevent the future incidences of cancer. Immune cells are primed to search and eliminate the cancerous cells due to which they are able to prevent relapse. Circulating cancerous cells are also targeted responsible for secondary cancer development is checked in the body. Efficacy of cancer vaccine could be monitored by checking PSA levels which may indicate improvement in patient's condition. However, these results may vary from patient to patient but significant improvement has been observed as compared to conventional therapeutic methods. Besides pharmacological benefits, this fact also reflects towards high marketing potential of prophylactic prostate cancer vaccine.

“Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015” Report Highlights:
- Introduction to Prostate Cancer Vaccine
- Mechanism of Prostate Cancer Vaccine
- Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase
- Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines
- Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines
- Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation)

Contents:
1. Introduction to Prostate Cancer Vaccine
2. Mechanism of Prostate Cancer Vaccine
3. Global Prostate Cancer Vaccine Market Dynamics
   3.1 Favorable Market Parameters
   3.2 Marketing & Commercialization Challenges
4. Global Prostate Cancer Vaccine Market Outlook
   4.1 Current Market Scenario
4.2 Global Prostate Cancer Vaccines Pipeline Overview

5. Global Prostate Cancer Vaccine Market Future Prospects

6. Personalized Cancer Vaccine Market Opportunities

7. Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase
   7.1 Research
   7.2 Preclinical
   7.3 Phase-I
   7.4 Phase-I/II
   7.5 Phase-II
   7.6 Phase-III

8. Marketed Prostate Cancer Vaccines by Company & Country

9. Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials
   9.1 No Development Reported
   9.2 Discontinued
   9.3 Suspended

10. Competitive Landscape
    10.1 Adamis Pharmaceuticals
    10.2 Aduro BioTech
    10.3 Bellicum Pharmaceuticals
    10.4 CytoVac
    10.5 Dendreon Corporation
    10.6 Generex Biotechnology Corporation
    10.7 Immunovaccine
    10.8 Oncbiomune
    10.9 Progenics
    10.10 Sotio

Table 6-1: Different Types of Biomarkers For Personalized Cancer Vaccine Development

Figure 1-1: Functions of Prostate Gland
Figure 1-2: Factors Responsible for Increasing Prostate Cancer Incidences
Figure 1-3: Different Methods of Prostate Cancer Treatment
Figure 2-1: Mechanism of Cancer Vaccines
Figure 2-2: Classification of Cancer Vaccines
Figure 2-3: Benefits of Prostate Cancer Vaccines
Figure 3-1: Drivers for Prostate Cancer Vaccines Market
Figure 3-2: Challenges for Prostate Cancer Vaccines Market
Figure 4-1: Prostate Cancer Vaccines Pipeline by Phase (%)
Figure 4-2: Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
Figure 4-3: No Development Reported in Prostate Cancer Vaccines Pipeline by Phase (%)
Figure 4-4: No Development Reported in Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
Figure 4-5: Discontinued Prostate Cancer Vaccines Pipeline by Phase (%)
Figure 4-6: Discontinued Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
Figure 4-7: Suspended Prostate Cancer Vaccines Pipeline by Phase (%)
Figure 4-8: Suspended Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
Figure 6-1: Personalized Cancer Vaccines Development Process
Figure 6-2: Personalized Cancer Vaccine Development Methodology
Figure 6-3: Skin Implant for Cancer Vaccine
Figure 10-1: Adamis Pharmaceuticals Pipeline
Figure 10-2: Bellicum Pharmaceuticals Pipeline
Figure 10-3: CytoVac Pipeline
Figure 10-4: Generex Biotechnology Clinical Pipeline Overview
Figure 10-5: Immunovaccine Clinical Pipeline Overview

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
Web Address: http://www.researchandmarkets.com/reports/3070534/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 1500</td>
</tr>
<tr>
<td>Single User</td>
<td></td>
</tr>
<tr>
<td>Hard Copy</td>
<td>USD 1800 + USD 61 Shipping/Handling</td>
</tr>
<tr>
<td>CD-ROM</td>
<td>USD 1800 + USD 61 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 3000</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td></td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.
* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World